Insider Buying: Kezar Life Sciences Inc (NASDAQ:KZR) Insider Purchases 5,000 Shares of Stock
Kezar Life Sciences Inc (NASDAQ:KZR) insider Christopher J. Kirk bought 5,000 shares of Kezar Life Sciences stock in a transaction dated Tuesday, August 13th. The stock was purchased at an average price of $4.61 per share, for a total transaction of $23,050.00. The purchase was disclosed in a filing with the SEC, which is available through this link.
Shares of NASDAQ:KZR traded up $0.10 on Thursday, hitting $4.83. The stock had a trading volume of 106,700 shares, compared to its average volume of 95,201. Kezar Life Sciences Inc has a twelve month low of $4.12 and a twelve month high of $36.33. The company has a quick ratio of 20.32, a current ratio of 20.32 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average of $6.15. The company has a market cap of $86.12 million, a P/E ratio of -2.14 and a beta of 0.61.
Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.02. On average, sell-side analysts forecast that Kezar Life Sciences Inc will post -1.98 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Kezar Life Sciences by 32.9% in the second quarter. BlackRock Inc. now owns 844,391 shares of the company’s stock valued at $6,512,000 after buying an additional 208,816 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Kezar Life Sciences by 105.7% during the 2nd quarter. Victory Capital Management Inc. now owns 461,453 shares of the company’s stock worth $3,558,000 after purchasing an additional 237,110 shares during the last quarter. Northern Trust Corp raised its holdings in Kezar Life Sciences by 4.6% during the 2nd quarter. Northern Trust Corp now owns 132,888 shares of the company’s stock worth $1,025,000 after purchasing an additional 5,882 shares during the last quarter. Morgan Stanley raised its holdings in Kezar Life Sciences by 923.4% during the 2nd quarter. Morgan Stanley now owns 74,982 shares of the company’s stock worth $578,000 after purchasing an additional 67,655 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Kezar Life Sciences by 126.7% during the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after purchasing an additional 32,441 shares during the last quarter. 50.97% of the stock is owned by institutional investors and hedge funds.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Recommended Story: What are the FAANG Stocks?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.